AstraZeneca(US:AZN) 智通财经网·2025-04-29 07:23Core Insights - AstraZeneca's Q1 2025 profits exceeded expectations, reaffirming its full-year guidance [1] - The company reported total revenue of $13.59 billion, which fell short of market expectations, while core EPS was $2.49, reflecting a 21% year-over-year increase [1] - Revenue growth was driven by double-digit increases in oncology and biopharmaceuticals, with a 10% year-over-year growth in total revenue [1] Revenue and Sales Performance - Sales of diabetes and heart disease drug Farxiga exceeded expectations by nearly 6%, and revenue from the newer oncology drug Enhertu also surpassed forecasts [1] - However, sales of other major oncology drugs were below expectations [1] Tax and Regulatory Issues - AstraZeneca may face a fine of up to $8 million due to alleged unpaid import taxes in China, with a suspected amount of $1.6 million identified [1] - The company previously estimated a potential fine of $4.5 million related to import taxes for two other oncology drugs, Imfinzi and Imjudo, which reassured analysts [2] Performance Guidance - AstraZeneca reaffirmed its revenue and core EPS guidance for FY 2025, expecting total revenue to grow at a high single-digit percentage and core EPS to grow at a double-digit percentage [3] - The company is committed to investing $3.5 billion in its U.S. operations by the end of 2026, focusing on R&D and manufacturing [3]